Life-saving effect and mechanism of action of thrombopoietin receptor agonist in radiation-exposed individuals

2016 Fiscal Year Final Research Report

• Project/Area Number: 25293256
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Hirosaki University
• Principal Investigator: KASHIWAKURA IKUO 弘前大学, 保健学研究科, 教授 (00177370)
• Co-Investigator(Kenkyū-buntansha): 吉野 浩教 弘前大学, 保健学研究科, 助教 (10583734) ; 門前 暁 弘前大学, 保健学研究科, 助教 (20514136) ; 伊藤 巧一 弘前大学, 保健学研究科, 教授 (90398579)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 被ばく医療 / TPO受容作動薬 / 造血幹細胞 / 急性放射性症候群

Outline of Final Research Achievements

The following three points were cited as research targets
1) Establishment of an optimal administration method of a thrombopoietin (TPO) receptor agonist in radiation-exposed individuals 2) Elucidation of the mechanism of action of lethal evasion of agonists in radiation-exposed individuals 3) Verification of the occurrence of adverse events in radiation-exposed individuals using a TPO receptor agonist romiplostim (RP) as a life-saving agent by long-term observation
The planned schedule for 3 years from the start of the research was largely adhered to. Administration of RP is optimal for 3 days after radiation exposure. RP acts on immature hematopoietic stem cells and vital stem cells of the gastrointestinal tract to promote long-term radiation reduction and regeneration. No adverse events were observed in radiation-exposed individuals using RP. Thus, we suggest that RP acts on recovery and regeneration of the hematopoietic and gastrointestinal systems from radiation damage.

Free Research Field

放射線生物学